Biocon's Kiran Mazumdar-Shaw Names Niece Claire as Successor, Plans Semaglutide Expansion by FY28
Kiran Mazumdar-Shaw names niece Claire as successor, targets semaglutide push from FY28; debt cut to $1.1 billion
The Economic Times
Image: The Economic Times
Kiran Mazumdar-Shaw, Executive Chairperson of Biocon, has announced a five-year succession plan for her niece, Claire Mazumdar, who will transition to the role of chairperson. The company aims to enhance its diabesity franchise, particularly with semaglutide, targeting significant contributions starting in FY28, while reducing debt to $1.1 billion.
- 01Claire Mazumdar will succeed Kiran Mazumdar-Shaw in a structured five-year transition.
- 02Biocon expects a strong product launch pipeline in the second half of FY27.
- 03The company targets significant contributions from semaglutide starting in FY28.
- 04Biocon's debt has been reduced to $1.1 billion, with ongoing efforts for further reduction.
- 05The R&D budget is set at 7-8% to support the biosimilar pipeline.
Advertisement
In-Article Ad
Kiran Mazumdar-Shaw, the Executive Chairperson of Biocon, confirmed a structured five-year succession plan for her niece, Claire Mazumdar, during the company's FY26 earnings call. Claire, who has experience as the founder of Bicara Therapeutics, will work alongside her aunt to learn the business before assuming the chairperson role. Meanwhile, Biocon is focusing on a strong product launch pipeline, particularly in the second half of FY27, with key products like Denosumab and Aflibercept entering the US market. The company anticipates that semaglutide will significantly contribute to its diabesity franchise starting in FY28, despite current competition. Biocon has successfully reduced its debt to $1.1 billion and is prioritizing further debt reduction with operational cash flow. The R&D budget is maintained at 7-8% to ensure a robust biosimilar pipeline, capitalizing on shortened regulatory pathways.
Advertisement
In-Article Ad
The company's focus on reducing debt and expanding its product pipeline may lead to improved financial stability and growth, potentially benefiting employees and stakeholders.
Advertisement
In-Article Ad
Reader Poll
Do you think Biocon's succession plan will ensure smooth leadership transition?
Connecting to poll...
More about Biocon
Read the original article
Visit the source for the complete story.